Marpai, Inc. (NASDAQ:MRAI) Director Damien Lamendola Acquires 100,000 Shares of Stock

Marpai, Inc. (NASDAQ:MRAIGet Rating) Director Damien Lamendola acquired 100,000 shares of the company’s stock in a transaction dated Monday, September 12th. The stock was bought at an average cost of $1.00 per share, for a total transaction of $100,000.00. Following the completion of the transaction, the director now directly owns 2,805,223 shares of the company’s stock, valued at $2,805,223. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Damien Lamendola also recently made the following trade(s):

  • On Wednesday, August 24th, Damien Lamendola acquired 135,944 shares of Marpai stock. The stock was bought at an average cost of $1.12 per share, for a total transaction of $152,257.28.
  • On Monday, August 22nd, Damien Lamendola purchased 44,346 shares of Marpai stock. The stock was acquired at an average price of $0.90 per share, for a total transaction of $39,911.40.
  • On Friday, August 19th, Damien Lamendola purchased 125,000 shares of Marpai stock. The stock was acquired at an average price of $0.96 per share, for a total transaction of $120,000.00.

Marpai Stock Down 4.7 %

Shares of Marpai stock opened at $0.95 on Wednesday. The company has a market capitalization of $19.58 million and a price-to-earnings ratio of -0.66. Marpai, Inc. has a 12-month low of $0.69 and a 12-month high of $6.31. The firm’s 50-day moving average price is $0.91 and its two-hundred day moving average price is $1.28.

Marpai (NASDAQ:MRAIGet Rating) last announced its quarterly earnings data on Wednesday, August 10th. The company reported ($0.34) earnings per share (EPS) for the quarter. The firm had revenue of $5.56 million for the quarter. Marpai had a negative return on equity of 115.72% and a negative net margin of 100.92%.

Analysts Set New Price Targets

Separately, Maxim Group started coverage on shares of Marpai in a research note on Monday, August 1st. They issued a “buy” rating and a $2.50 price target on the stock.

Institutional Investors Weigh In On Marpai

A hedge fund recently raised its stake in Marpai stock. Vanguard Group Inc. boosted its position in shares of Marpai, Inc. (NASDAQ:MRAIGet Rating) by 63.0% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 363,332 shares of the company’s stock after buying an additional 140,407 shares during the period. Vanguard Group Inc. owned approximately 1.79% of Marpai worth $654,000 at the end of the most recent quarter. 35.02% of the stock is owned by institutional investors.

About Marpai

(Get Rating)

Marpai, Inc, a technology-driven healthcare payer, focuses on providing services to the self-insured employer market in the United States and Israel. The company offers ancillary services, such as care management, case management, actuarial services, health savings account administration, and cost containment services.

Read More

Insider Buying and Selling by Quarter for Marpai (NASDAQ:MRAI)

Receive News & Ratings for Marpai Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marpai and related companies with MarketBeat.com's FREE daily email newsletter.